Form 4: Sana Biotechnology Director Receives Stock Option Grant
Director Equity Compensation Disclosure
Director Patrick Y. Yang was granted 90,000 stock options in Sana Biotechnology, Inc. as part of standard equity compensation.
Summary
- Director Patrick Y. Yang received a grant of 90,000 stock options on June 4, 2026.
- The options have an exercise price of $2.96 per share.
- The options are set to expire on June 3, 2036.
- The grant vests 100% on the earlier of June 4, 2027, or immediately prior to the 2027 annual meeting of stockholders.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral administrative filing regarding routine director compensation that does not signal a change in company fundamentals.
Positives
- Alignment of director interests with long-term shareholder value through equity-based compensation.
Negatives
- The grant results in potential future dilution for existing shareholders.
Risks
- Market volatility affecting the value of the underlying common stock.
- The director's ability to vest the options is contingent upon continuous service to the company.
Future Outlook
The filing does not provide forward-looking financial guidance, focusing solely on the disclosure of director equity compensation.
Industry Context
StockSavvy.ai notes that equity grants to board members are standard practice in the biotechnology sector to incentivize long-term oversight and strategic alignment, particularly for companies in the clinical development stage.
Comparison to Industry Standards
- The grant of 90,000 options is consistent with typical non-employee director compensation packages for mid-cap biotechnology firms.
- The one-year cliff vesting schedule is a standard retention mechanism for board members in the life sciences industry.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Power of Attorney | Formalized Power of Attorney for SEC filing purposes. | 2025-10-29 | Administrative update to ensure timely regulatory compliance. |
Stakeholder Impact
- Minor dilution impact on existing shareholders upon potential future exercise of options.
Next Steps
- Vesting of options on June 4, 2027, or prior to the 2027 annual meeting.
Key Dates
| Date | Description |
|---|---|
| 2025-10-29 | Date of Power of Attorney execution. |
| 2026-06-04 | Date of stock option grant. |
| 2027-06-04 | Vesting date for the stock options. |
| 2036-06-03 | Expiration date for the stock options. |
Keywords
Sana Biotechnology, SANA, Director Compensation, Stock Options, Insider Transaction, Equity Grant
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.